Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2722644 | 0.72 | L3MBTL1 (0.65) | ALDH1A1L3MBTL1RAB9ANPC1GAA | |
| SCHEMBL6710865 | 0.71 | ALDH1A1 (1.00) | ALDH1A1ALOX15L3MBTL1RAB9ANPC1 | |
| SCHEMBL7981204 | 0.71 | CTNNB1 (0.60) | ALDH1A1L3MBTL1RAB9ANPC1TSHR | |
| SCHEMBL28408612 | 0.71 | RAB9A (0.71) | ALDH1A1ALOX15L3MBTL1RAB9ANPC1 | |
| SCHEMBL22362717 | 0.70 | LMNA (0.63) | ALDH1A1ALOX15L3MBTL1RAB9ANPC1 | |
| SCHEMBL10412713 | 0.70 | RAB9A (0.60) | ALDH1A1L3MBTL1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL30454690 | 0.70 | RAB9A (0.60) | ALDH1A1L3MBTL1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6011931 | 0.70 | RAB9A (0.75) | ALDH1A1ALOX15RAB9ANPC1GAA | |
| SCHEMBL14760273 | 0.70 | RAB9A (0.51) | ALDH1A1RAB9ANPC1TSHRSMN1; SMN2 | |
| SCHEMBL2051943 | 0.70 | RAB9A (0.75) | ALDH1A1ALOX15RAB9ANPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897198-B2 | Method of treatment with combinations of statin and aryl-substituted propanolamine derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH | 2005-05-24 | — | — | US | disclosed |
| EP-1117645-B1 | ARYL-SUBSTITUTED PROPANOLAMINE DERIVATIVES, METHODS FOR THEIR PRODUCTION, MEDICAMENTS CONTAINING SAID COMPOUNDS AND THEIR USE | AVENTIS PHARMA GMBH (DE) | 2004-05-06 | — | — | EP | disclosed |
| US-20030195145-A1 | Methods of treatment with combinations of statin and aryl-substituted propanolamine derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-10-16 | — | — | US | disclosed |
| US-6569835-B2 | Hypolipidemics; treating obesity and disorders of lipid metabolism | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-27 | — | — | US | disclosed |
| US-6566340-B2 | Antilipemic agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-20 | — | — | US | disclosed |
| US-20020177610-A1 | Combinations with statin and aryl-substituted propanolamine derivatives, their preparation, pharmaceuticals comprising them, and their use | AVENTIS PHARMA DEUTSCHLAND GMBH | 2002-11-28 | — | — | US | disclosed |
| US-20020042381-A1 | Aryl-substituted propanolamine derivatives, their preparation, pharmaceuticals comprising them, and their use | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH | 2002-04-11 | — | — | US | disclosed |
| EP-1117645-A1 | ARYL-SUBSTITUTED PROPANOLAMINE DERIVATIVES, METHODS FOR THEIR PRODUCTION, MEDICAMENTS CONTAINING SAID COMPOUNDS AND THEIR USE | Aventis Pharma Deutschland GmbH (DE) | 2001-07-25 | — | — | EP | disclosed |
| US-6245744-B1 | ANTILIPEMIC AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-06-12 | — | — | US | disclosed |
| WO-2000020392-A1 | ARYL-SUBSTITUTED PROPANOLAMINE DERIVATIVES, METHODS FOR THEIR PRODUCTION, MEDICAMENTS CONTAINING SAID COMPOUNDS AND THEIR USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042381-A1 | Aryl-substituted propanolamine derivatives, their preparation, pharmaceuticals comprising them, and their use | ADRB1, ADRB3, ADRB2 | ALDH1A1 93/4885ALOX15 757/4885L3MBTL1 3573/4885 |
| US-20030195145-A1 | Methods of treatment with combinations of statin and aryl-substituted propanolamine derivatives | CYP11B1, HMGCR, CYP27A1 | ALDH1A1 229/4885ALOX15 337/4885L3MBTL1 3554/4885 |
| US-20020177610-A1 | Combinations with statin and aryl-substituted propanolamine derivatives, their preparation, pharmaceuticals comprising them, and their use | ADRB3, ADRB1, CYP11B1 | ALDH1A1 276/4885ALOX15 411/4885L3MBTL1 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.